Moderna cuts 2025 sales forecast by $1 billion on weak vaccine demand, shares fall
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19
Moderna shares slide as it slashes revenue forecast
Moderna slashed its 2025 revenue projection by $1bn on Monday, citing reduced demand for its Covid-19 and respiratory syncytial virus (RSV) vaccines.
Moderna shares plunge after company cuts vaccine sales outlook
The Cambridge-based company said it expects 2025 revenue of between $1.5 billion to $2.5 billion, down from its previous projection of between $2.5 billion and $3.5 billion.
Moderna cuts 2025 sales forecast by $1 bln on weak vaccine demand, shares tumble
Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) shot and weak demand for COVID-19 vaccines, sending its shares down more than 24% in early trading.
Moderna Shares Drop to Five-Year Low After Slashing Revenue, Sales Forecasts
Moderna's stock plummeted to an almost five-year low after the biotech company cut its revenue outlook for this year and said that sales for last year will come in at the lower end of its guidance. Shares fell 22% to $33.
Moderna shares plunge as company dramatically lowers sales forecast
Axios Visuals Moderna shares plunged today to lows not seen since the early weeks of the pandemic after the company dramatically lowered its sales forecast. Zoom in: Waning demand for COVID vaccines is crushing Moderna's revenue.
Moderna Cuts 2025 Revenue Forecast by $1 Billion, Shares Drop 17% As Investors Eye $30 Support Level
Moderna shares tumbled nearly 17% on Monday after the drugmaker slashed its 2025 revenue forecast by $1 billion and announced plans to cut $1.5 billion in expenses this year. The company faces challenges balancing rising drug development costs with declining demand for Covid-19 treatments and slow adoption of its RSV medication.
justthenews9d
Moderna buried child's death in COVID booster trial in EU report, FDA response called 'misleading'
Stock-plunging mRNA vaccine maker, already in bed with feds on vaccine royalties, says booster not "causally" related without ...
Monthly Prescribing Reference1d
Moderna Provides Update on Norovirus Vaccine Candidate
Moderna’s mRNA-1403 is a messenger RNA-based trivalent vaccine candidate designed to protect against multiple norovirus genotypes. Moderna provided an update on the status of its trial investigating a ...
Time5d
A Norovirus Vaccine May Be Coming
There is no antiviral treatment for the miserable but thankfully short-lived illness, and no vaccine—yet. But scientists at Moderna are in the late stages of testing what could be the first such ...
THE WEEK7d
How close are we to a norovirus vaccine?
Norovirus, often erroneously called the "stomach flu," sickens an estimated 21 million Americans and 685 million people worldwide every year, and though there is currently no preventive vaccine ...
Yahoo Finance2d
Moderna surprises the Street by predicting a bigger-than-expected sales drop
Shares of Moderna tumbled in early trading Monday after the vaccine maker predicted a steeper-than-expected sales drop in the new year. Moderna said it expects 2025 revenue to range between $1.5 ...
FiercePharma3d
JPM25: Moderna slashes guidance, plots $1B in cost cuts this year amid lackluster vaccine sales
Earlier this month, Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s lackluster vaccine sales in COVID-19 and respiratory ...
Moderna May Have The Best Shot At A Vaccine For Stomach Flu
Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.
Moderna’s Struggles Could Complicate Bird Flu Fight. What It Means for a Potential Vaccine.
Moderna continues to cut costs, which could raise questions about the vaccine playbook used during the Covid-19 pandemic.